Metastasis-associated lung adenocarcinoma transcript 1(MALAT1)is a well-established oncogenic long non-coding RNA,the higher expression of which is strongly correlated with cancer events such as tumorigenesis,progression,metastasis,drug resistance,and treatment outcome in solid cancers.Recently,a series of studies has highlighted its potential role in hematological malig-nancies in terms of these events.Similar to solid cancers,MALAT1 can regulate various target genes via sponging and epigenetic mechanisms,but the miRNAs sponged by MALAT1 differ from those identified in solid cancers.In this review,we systematically describe the role and underlying mechanisms of MALAT1 in multiple types of hematological malignancies,including regulation of cell proliferation,metastasis,stress response,and glycolysis.Clinically,MALAT1 expression is related to poor treatment outcome and drug resistance,therefore exhibiting potential prognostic value in multiple myeloma,lymphoma,and leukemia.Finally,we discuss the evaluation of MALAT1 as a novel therapeutic target against cancer in preclinical studies.
Chunlan Zhang;Yun Qin;Yu Wu;Heng Xu;Yang Shu
Department of Hematology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,ChinaDepartment of Radiology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,ChinaDepartment of Laboratory Medicine/Research Center of Clinical Laboratory Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China||Department of Biotherapy,State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China||Institute of General Surgery,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,ChinaDepartment of Biotherapy,State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China||Department of General Surgery,Gastric Cancer Center and Laboratory of Gastric Cancer,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China
Long non-coding RNA;MALAT1;Hematological malignancies;Tumorigenesis;Metastasis;Drug resistance;Prognostic biomarker
《中华医学杂志（英文版）》 2024 (010)
1151-1159 / 9
This study was supported by grants from the National Natural Science Foundation of China(Nos.81973408 and 82273445),the 1.3.5 Project for Disciplines of Excel-lence,West China Hospital,and Sichuan University(No.ZYYC20003).
10.1097/CM9.0000000000003090
评论